MAPT and supranuclear palsy, progressive, 1: The PSP-RS/PI phenotype had shorter disease duration than the other phenotypes (PSP-P + PSP-Cx) in the resultant groups after applying Respondek's and MDS-PSP criteria (MDS-6y and MDS-Last), adjusting for age at onset and total tau burden (Supplementary Table 3).